GuLP-1 UK sells peptide compounds marketed around GLP-1 receptor agonists, operating in a legally murky space where products are sold as 'research chemicals' to sidestep medicines regulation. The MHRA does not licence these products for human use, and UK consumers buying them face real safety and legal risks. Until regulatory clarity exists, this brand warrants significant caution.
GuLP-1 UK (gulp-1.com) is a recently established website selling peptide products in the GLP-1 category — compounds chemically related to prescription medicines such as semaglutide (Ozempic/Wegovy) and tirzepatide. The site appears to be UK-facing but carries no verifiable Companies House registration, no named directors, and no physical trading address, which are all significant red flags for a health-related retailer.
The core legal problem is that GLP-1 peptides sold for human use require MHRA licensing as medicines in the UK. Sites like this typically label products as 'for research purposes only' to avoid that classification, but UK trading standards and the MHRA have repeatedly stated this disclaimer does not automatically make such products legal to sell. Consumers injecting unverified peptides from unlicensed suppliers face unknown purity, dosage accuracy, and contamination risks with no regulatory safety net.
UK consumers should be aware that purchasing from this type of supplier means no MHRA safety oversight, no consumer protection under UK medicines law, and very limited financial recourse beyond a credit card chargeback if something goes wrong. Anyone seeking GLP-1 treatments should consult a registered UK prescriber and use MHRA-regulated pharmacies. We strongly advise against purchasing from GuLP-1 UK until it demonstrates proper regulatory compliance.